RXST FRAUD NOTICE: RxSight, Inc. Hit with Securities Class Action after 38% Stock Drop – Investors Urged to Contact BFA Law

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3]. Financial Performance and Issues - The company previously reported strong sales of LAL and Light Delivery Devices (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulting in another 38% drop in stock price, from $12.79 to $7.95 per share [6].